全球化學資訊學市場：預測（2023-2028）

全球化學資訊學市場規模預計在預測期內將以 14.67% 的複合年成長率成長。

慢性病盛行率的上升以及相應的開發新治療方法的需求是一些關鍵促進因素。其他重要因素包括檢驗組合化學方法可能開發的各種藥物的重要性日益增加，以及對分子和原子反應過程中產生的資料進行有效管理的需求日益成長，其中包括日益關注和投資數量的增加支持研發工作。此外，新藥的開拓、檢驗組合化學方法創建的各種候選藥物的重要性日益增加，以及不斷增加的研發力度正在推動化學資訊學市場的發展。

增加藥物研發的創新與進步

市場推動因素之一是藥物研發過程的進步和創新。化學資訊學在藥物研發過程中有許多應用，包括化合物選擇、虛擬庫開發、虛擬高通量篩檢、HTS資料探勘和電腦 ADMET。例如，根據 2021 年 6 月出版的題為“Cheminformatics Approaches in the Discovery of Drugs for Neglected Tropical Medicines”的學術期刊報道，化學資訊學已成為藥物研發過程中的基本要素，加快了尋找具有所需理化性質的新化學實體的速度。 、藥理學、毒理學和藥物動力學特性。因此，化學資訊學的市場規模預計將因這些因素而擴大。

化學分析的需求增加

化學資訊學是一門結合化學和資訊學的學科，旨在解決分子建模、藥物開發、生物資訊學和生物資料庫中的問題。化學資訊學可以幫助克服分子多樣性、高通量篩檢(HTS) 以及小分子和化合物虛擬庫的挑戰。此外，我們還協助創建大型化合物集合的資料庫，這些資料庫使用計算技術來根據各種屬性搜尋正在分析的庫。該領域在創新藥物創造中的受歡迎是因為該領域所使用的技術廣泛適用於藥物開發的所有領域，包括目標識別和3D結構的建構。

擴大虛擬篩檢在藥物研發的應用

虛擬篩檢技術用於利用化學資訊學技術的藥物研發。虛擬篩檢可用於根據溶解度和 ADMET 特性等參數從庫中去除不需要的化合物。大型In Silico文庫也可以透過這種方式進行篩檢，以找到具有合適特性的化合物並在實驗高通量篩檢之前收集資料。使用適合研究化學空間、動態和藥物動力學特徵的創新虛擬篩檢方法對大型化合物庫進行了In Silico評估。因此，發現新化合物過程中的成本、基礎設施和時間都減少了。

個體化醫療意識不斷增強

由於慢性病的不永續嚴重性，人們對個人化醫療的認知不斷提高，以及對有效藥物的需求正在推動開發新藥，並對化學資訊市場佔有率的擴大產生積極影響。這些技術廣泛應用於藥物設計過程的各個階段。尋找具有預測成功率的有效先導標靶的方法將永遠改變藥物的發現方式，並增加降低高藥物損耗率的努力成功的可能性。此外，由於研發強度的增加，技術創新的貢獻正在加強該領域。

北美預計將主導化學資訊學市場

預計北美地區將在預測期內引領化學資訊學市場。加速藥物研發的生物技術融資的成長以及該地區許多重要參與者的存在是推動擴張的因素。其他原因包括疾病傳播。例如，根據美國健康信託組織2020年發布的報告，美國成人肥胖率約為42.4%，首次超過40.0%的基準值。自2008年以來，全國成年人肥胖率增加了26.0%。

設備成本高

NGS 技術的進步增加了對快速、高精度和方便用戶使用的生物資訊學工具的需求。並非所有進行實驗研究的科學家都是化學資訊學家。因此，擁有易於使用的工具來利用生物資訊系統極為重要。許多化學資訊學程式缺乏合適的方便用戶使用介面，並且通常需要大量的電腦知識。基因組分析設備的成本從 1000 萬美元到 2000 萬美元不等，但由於其增強的特性和功能，同樣昂貴。製藥公司和研究機構需要大量此類系統，因此花費大量資金購買多種基因組儀器。

主要市場產品

• 2022年9月，OpenEye Scientific Software被美國電腦軟體公司Cadence Design Systems收購，收購價格未公開。此次收購將 Cadence 在計算軟體方面的核心能力擴展到生命科學分子建模和仿真，從而推進了 Cadence 的智慧型系統設計 (Intelligent System DesignTM) 方法。分子建模和化學資訊軟體由美國軟體公司 OpenEye Scientific Software 提供。 2022年7月，結合科學、資料和決策的研發科學軟體領導者Dotmatics藥物研發方案。該解決方案利用該公司在小分子藥物研究方面超過 15 年的經驗開發的最佳實踐，使公司能夠更輕鬆地進行創新。 2022 年 7 月，Dotmatics 的新化學軟體可用於小分子藥物發現。該平台促進研究團隊的溝通和效率，同時最大限度地減少業務浪費並實現資料主導的決策。新計劃還提供了藥物開發步驟的模板，從先導化合物最佳化研究到命中化合物鑑定。

目錄

第1章簡介

• 市場概況
• 市場定義
• 調查範圍
• 市場區隔
• 貨幣
• 先決條件
• 基準年和預測年時間表

第2章調查方法

• 調查資料
• 先決條件

第3章執行摘要

• 研究亮點

第4章市場動態

• 市場促進因素
• 市場抑制因素
• 波特五力分析
• 產業價值鏈分析

第5章化學資訊學市場：依應用分類

• 介紹
• 藥物研發
• 化學分析
• 藥品檢驗
• 其他

第6章化學資訊學市場：依最終用途

• 介紹
• 化學品
• 藥品
• 研究/學術機構
• 監管中心
• 其他

第7章化學資訊學市場：按地區

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
• 中東/非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 其他
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 印尼
  • 台灣
  • 其他

第8章競爭環境及分析

• 主要企業及策略分析
• 新興企業和市場盈利
• 合併、收購、協議和合作
• 供應商競爭力矩陣

第9章 公司簡介

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• BioSolveIT GmbH
• BIOVIA（Dassault Systemes）
• ChemAxon, Inc.
• Eurofins CEREP SA（Eurofins Panlabs Inc.）
• Jubilant Biosys Inc.
• Molecular Discovery Ltd.
• OpenEye Scientific Software Inc.
• Schrodinger Inc.

The Chemoinformatics market is estimated to grow at a CAGR of 14.67% during the forecast period.

The rising incidence of chronic diseases and the corresponding need to develop novel treatments are a few major drivers. Other important factors include the growing significance of validating the variety of possible medications developed by combinatorial chemical methods, the rising emphasis on the efficient management of data produced during molecular and atomic reactions, and the rising number of investments sustaining R&D efforts. Moreover, the development of novel medications the growing significance of validating the wide range of potential drug candidates created by combinatorial chemical methods, and the rising number of R&D efforts are fueling the chemoinformatics market.

Rising innovations and advancements in drug discovery

One of the major market drivers is the advancement and innovation in the drug development process. Cheminformatics has many uses in the drug discovery process, including compound selection, virtual library development, virtual high throughput screening, HTS data mining, and in silico ADMET. For instance, cheminformatics has become an essential component of the drug discovery process and expedites the search for new chemicals with needed physicochemical, pharmacological, toxicological, and pharmacokinetic properties, according to the journal titled "Cheminformatics Approaches in the Discovery of Drugs for Neglected Tropical Diseases" published in June 2021. Therefore, it is expected that these factors will increase the chemoinformatics market size.

Increasing demand for chemical analysis

Cheminformatics is a discipline that combines chemistry and informatics to address problems in molecular modelling, drug development, bioinformatics, and biological databases. Cheminformatics aids in overcoming issues with molecular diversity, high-throughput screening (HTS), and virtual libraries of small molecules or compounds. Additionally, it aids in the creation of a database of sizable compound collections that uses computational techniques to search the library during analysis based on different properties. The popularity of the field in the creation of innovative medications is a result of the technologies used in it being widely applicable across the spectrum of drug development, including target identification and 3D structure construction.

Rising use of virtual screening for drug discovery

Virtual screening technique is used in drug discovery using cheminformatics methods. Based on parameters like solubility and ADMET characteristics, virtual screening can be used to remove undesirable compounds from libraries. Large in silico libraries can also be screened using this method to find compounds with the appropriate properties and to gather data before experimental high-throughput screening. Large libraries of compounds were evaluated in silico using innovative virtual screening methodologies, which favoured the examination of their chemical space, pharmacodynamics, and pharmacokinetic features. As a result, less money, infrastructure, and time were expended during the process of discovering new chemical entities.

Increasing awareness of personalized medicines

The desire for effective medication driven by rising awareness of personalized medicine and the unsustainable weight of chronic diseases serves as an impetus for new drug development, which favourably affects the expansion of the chemoinformatics market share. These methods are used in a wide range of stages of the drug-designing process. The approach of finding effective lead targets with predicted success rates has completely changed how drugs are discovered, increasing the likelihood that efforts to reduce the high attrition rates of drugs will be successful. Additionally, the sector is strengthened due to the contributions of technological innovation as a result of the increasing R&D intensity.

North America is projected to dominate the chemoinformatics market

During the projected period, the North American region is anticipated to lead the chemoinformatics market. Increased financing for biotechnology sectors to speed up drug discovery and the presence of many important players in the area are some of the factors contributing to the expansion. Other causes include rising disease prevalence. For instance, according to a report released in 2020 by the Trust for America's Health Organisation, the adult obesity rate in the United States is around 42.4%, and for the first time, the national rate has been above the 40.0% threshold. Since 2008, there has been a 26.0% nationwide increase in the adult obesity rate.

High equipment cost

NGS technology advancements have increased the demand for rapid, precise, and user-friendly bioinformatics tools. Not all scientists conducting experimental research are chemoinformaticians. Because of this, having accessible tools is crucial for using bioinformatics systems. Because many chemoinformatics programmes lack an appropriate user-friendly interface, they frequently require significant computer knowledge. The cost of genomic instruments, which ranges from $10 million to $20 million, is similarly premium due to their enhanced features and functions. Pharmaceutical businesses and research labs spend a lot of capital money buying several genomic equipment because they need so many of these systems. which impedes the chemoinformatics market.

Market key products

• In September 2022, OpenEye Scientific Software was acquired by American computer software company Cadence Design Systems for an undisclosed price. By expanding Cadence's core competency in computational software to include life sciences molecular modelling and simulation, the acquisition advances Cadence's Intelligent System DesignTM approach. Software for molecular modelling and cheminformatics is offered by the American software company OpenEye Scientific Software.
• In July 2022, the Small Molecule Drug Discovery Solution, which is an integrated scientific R&D platform with prepared workflows and enhanced data management capabilities, has been released by Dotmatics, a leader in R&D scientific software combining science, data, and decision-making. By using best practices developed from the company's more than 15 years of experience enabling small molecule drug research, the solution enables businesses to innovate more readily
• In July 2022, new chemical software from Dotmatics was made available for finding small-molecule medicines. The platform encourages research team communication and efficiency while minimising operational waste and allowing data-driven decision-making. The new programme also comes with templates for drug development procedures, from lead optimisation studies to hit identification.

Segmentation:

By Application

• Drug Discovery
• Chemical Analysis
• Drug Validation
• Others

By End-Use

• Chemical
• Pharmaceutical
• Research and Academic Institutions
• Regulatory Centers
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. CHEMOINFORMATICS MARKET, BY APPLICATION

• 5.1. Introduction
• 5.2. Drug Discovery
• 5.3. Chemical Analysis
• 5.4. Drug Validation
• 5.5. Others

6. CHEMOINFORMATICS MARKET, BY END-USE

• 6.1. Introduction
• 6.2. Chemical
• 6.3. Pharmaceutical
• 6.4. Research and Academic Institutions
• 6.5. Regulatory Centers
• 6.6. Others

7. CHEMOINFORMATICS MARKET, BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East And Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Israel
  • 7.5.4. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. Japan
  • 7.6.3. India
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Taiwan
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrativeness
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

• 9.1. Agilent Technologies Inc.
• 9.2. Bio-Rad Laboratories Inc.
• 9.3. BioSolveIT GmbH
• 9.4. BIOVIA (Dassault Systemes)
• 9.5. ChemAxon, Inc.
• 9.6. Eurofins CEREP SA (Eurofins Panlabs Inc.)
• 9.7. Jubilant Biosys Inc.
• 9.8. Molecular Discovery Ltd.
• 9.9. OpenEye Scientific Software Inc.
• 9.10. Schrodinger Inc.